LSE · DXRX.L
Diaceutics PLC
£2.04£0.00 (0.0%)
Diaceutics PLC’s quoted price sits in the upper half of its reported 52-week range, 3.1% below the high.
Loading market information…
LSE · BVXP.L · GBp
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 05:15 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
Bioventix PLC’s quoted price sits in the upper half of its reported 52-week range, 10.2% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Bioventix PLC’s forward annual dividend is £1.40 per share, paid semi-annual. The forward yield is 6.91% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Bioventix PLC’s next earnings report is currently expected on Mar 29, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Bioventix PLC’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Bioventix PLC focuses on the development, manufacturing, and global provision of sheep monoclonal antibodies (SMAs) for various diagnostic purposes. The company's extensive product line features purified SMAs that facilitate testing for critical areas such as thyroid conditions, vitamin D deficiencies, cardiac health markers, detection of drugs of abuse, fertility assessments, infectious diseases, oncology, and other diverse medical indications. Additionally, Bioventix PLC offers tailored contract SMA development and specialized recombinant services. The London, UK-based firm was established in 2003.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:05 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2022 |
|---|
| Mar 27, 2023 |
| £0.71-3.27% vs estimate |
| £5.90M-0.08% vs estimate |
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£2.04£0.00 (0.0%)
Diaceutics PLC’s quoted price sits in the upper half of its reported 52-week range, 3.1% below the high.
£0.89£0.00 (0.0%)
Scancell Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 69.83% below the high.
£0.24+£0.00 (+1.93%)
EKF Diagnostics Holdings plc’s quoted price sits in the lower half of its reported 52-week range, 18.1% below the high.
£5.30£0.00 (0.0%)
4basebio PLC’s quoted price sits in the lower half of its reported 52-week range, 35.37% below the high.
£0.10+£0.00 (+2.63%)
Ondine Biomedical Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.1% below the high.
£6.80+£0.07 (+1.04%)
Hemogenyx Pharmaceuticals Plc’s quoted price sits in the lower half of its reported 52-week range, 44.26% below the high.
£0.06+£0.00 (+8.11%)
hVIVO plc’s quoted price sits in the lower half of its reported 52-week range, 45.45% below the high.
£0.83£0.00 (0.0%)
Arecor Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 13.16% below the high.
